Bovine Respiratory Disease Vaccines Research Articles

Influence of autolyzed yeast on the health of immunologically immature calves

Autolyzed yeast is a supplement option for calves due to its ability to stimulate the immune system and performance; however, there are few studies about the effect of different yeast derivatives. Autolyzed yeast is rich in immunomodulatory substances, such as mannan oligosaccharides and β-glucans. These substances enhance the innate and humoral immunity of calves, resulting in greater intestinal and respiratory health. Thus, the objective of the study was to evaluate whether supplementation with autolyzed yeast improves the health of calves, in the challenge of naturally acquired Eimeriosis and bovine respiratory disease (BRD). Twenty Holstein calves aged 15 days, which had already suckled colostrum, were studied for 36 days. At 15 days of life all animals had naturally acquired Eimeriosis. They were challenged with an intranasal BRD vaccine at 30 days of age. The Supplemented group (n=10) received autolyzed yeast (10 g animal -1 day -1), once a day in milk for 36 days, and the Control group (n=10) was not supplemented throughout the experiment. Blood neutrophil: lymphocyte ratio, oxidative metabolism of neutrophils (OM), serum immunoglobulins and haptoglobin, occurrence of diarrhea, BRD, and weight gain were measured. After vaccination, all animals increased the blood neutrophil: lymphocyte ratio, but only the control group showed a 20% reduction in OM three days after the vaccine. The supplement affected the immune response, preserving OM, increasing serum IgA levels by 10% (P=0.006), and reducing haptoglobin serum levels (P=0.05). In addition, the supplement attenuated diarrhea and BRD, which allowed for greater weekly weight gain (difference of 2 kg between treatments, P<0.05), concluding that the autolyzed yeast showed some evidence that it can increase the health of calves challenged with Eimeriosis and the BRD vaccine.

Does the immune stimulant Amplimune® modulate humoral and cytokine responses to commercial bovine respiratory disease vaccines in cattle?

Context Feedlot entry can be a period of stress for cattle due to transportation, altered diets and other influences. Stress can suppress host defence mechanisms. Innate immune stimulants, such as mycobacterial cell-wall fractions, attract attention for the primary objective of enhancing non-specific immune resistance of cattle against microbial diseases during periods of stress-induced susceptibility. These stimulants are also recognised for their capacity to modify responses of the adaptive immune system to vaccines. Aims This study aims to evaluate the potential for mycobacterial cell-wall fractions in Amplimune® to modify adaptive immune responses to the commercial vaccines Rhinogard® (modified live bovine alphaherpesvirus-1 (BoHV-1)) and Bovilis MH + IBR® (inactivated Mannheimia haemolytica and BoHV-1) in yearling cattle during simulated feedlot induction. Methods Fifty-four mixed-sex Angus yearling cattle were transported for 6 h on Day −1 and on Day 0. The cattle were assigned to the following six treatment groups (n = 9/group): Rhinogard plus 2 mL Amplimune, Rhinogard plus 5 mL Amplimune, Bovilis MH + IBR plus 2 mL Amplimune, Bovilis MH + IBR plus 5 mL Amplimune, Rhinogard plus 5 mL saline, and Bovilis MH + IBR plus 5 mL saline. Blood and nasal secretions were sampled at various time points following treatment and antigen-specific antibody (immunoglobulin G) responses to components of the vaccines were assessed. Interferon-γ production by peripheral blood mononuclear cells in response to BoHV-1, Concanavalin A or media only were assessed. Key results No adverse clinical reactions were observed to administration of Amplimune and vaccines. A systemic antibody response to vaccination was observed for the Bovilis MH + IBR vaccine. Vaccine-specific antibody and cytokine responses were not modified by Amplimune. Conclusions Amplimune can be administered at the same time as Rhinogard or Bovilis MH + IBR vaccines, without undesirable effects on specific immune responses to vaccination. Implications The primary interest in using Amplimune is to potentiate non-specific immune defences as an alternative to antibiotics for the prevention and/or treatment of microbial diseases such as bovine respiratory disease in production animals. In view of its adjuvant-like activities, administration of Amplimune might also confer beneficial or detrimental effects on antigen-specific responses of the adaptive immune system to contemporaneous vaccination.

Imunoestimulação da resposta broncoalveolar de bezerros vacinados contra complexo respiratório bovino

ABSTRACT: Although intranasal bovine respiratory disease (BRD) vaccines containing live attenuated virus elicit greater stimulation of local humoral immunity response, they can mimic a viral infection, responsible for reducing innate defense during the establishment of vaccine-induced immunity. Probiotics containing Saccharomyces cerevisiae or Enterococcus faecium reduced the occurrence of BRD in neonatal calves challenged with the bovine respiratory syncytial virus (BRSV). Furthermore, the probiotics potentiated the humoral immune response after vaccination in murine models, raising the question of whether they could have the same effect in calves. This study aimed to verify if the probiotic containing E. faecium and S. cerevisiae attenuates the inflammation caused by the vaccine against BRD in the respiratory tract region in calves. Twenty-four healthy Jersey calves, aged 6 to 7 months old, were divided into the groups: control (C), supplemented (S), vaccinated (V), and supplemented and vaccinated (SV), with six animals in each of them. Supplemented groups (S and SV) received S. cerevisiae and E. faecium once a day on D-15 for 51 days (Probios precise®, Ouro Fino®, 2g/day/animal). Vaccinated groups (V and SV) received a single dose of an intranasal BRD vaccine on day 0 (Inforce®, Zoetis®, 1ml/ nostril). The control group was not supplemented or vaccined. Irritation of the respiratory tract and bronchoalveolar (BA) evaluations: cytology, phagocyte function, and IgA were measured on D-15, D3, D7, and D21. The vaccinated groups showed greater irritation of the nasopharynx and trachea. However, only Group V showed a reduction in BA phagocyte function and an increase in cellularity by a neutrophil influx in the BA region. Regarding IgA BA, SV showed the greatest increase, followed by S and V, concerning C. We conclude that isolated supplementation with E. faecium and S. cerevisiae promoted increased production of BA IgA. In association with the vaccine, the supplementation attenuated the inflammation of the respiratory tract produced by the vaccine itself, avoiding the reduction of phagocyte function BA, besides potentiating the humoral immune response of the vaccine containing live attenuated virus against BRD.

Dam Age Differentially Affects Immune Response of Her Calf to Bovine Respiratory Disease Vaccination

Understanding the biological factors that affect immunological responses may be beneficial in developing more effective bovine respiratory disease vaccination strategies. Dam traits, such as age and vaccination history, are not considered when developing vaccination protocols or assessing vaccination efficacy, even though both factors may influence the transference of passive immunity; therefore, a preliminary study was conducted to determine the effect of dam age on the immune response of their calves to vaccinations. Calves born to dams of various ages were vaccinated with a modified live vaccine at 3 to 4 months old, revaccinated with either the same modified live or an inactivated vaccine at weaning, and boosted with the same vaccine 28 days later. Immune and cortisol measures were taken upon initial vaccination, revaccination at weaning, and then 14 and 28 days post-revaccination and post-booster. Overall, calves from older-aged dams began to exhibit a pattern indicative of a dampened immunoglobulin-G response to revaccination and booster, regardless of vaccination type. In contrast, calves from the youngest and oldest dams who received one modified live and two inactivated vaccines had the highest serum-neutralizing titers for most antigens present in the vaccines. These preliminary data partly imply that it may be plausible that the more doses of modified live vaccines the dam receives, which increase with each pregnancy, may affect the immune response of her progeny to vaccination at weaning and revaccination. This may be due to the effects on maternal passive immunity and is further affected by the type of vaccination her progeny received for some measures. However, more research is necessary to elucidate further the effects biological factors have on the immune response to vaccination, develop better vaccination strategies, and further validate these findings through increased sample sizes.

Effect of on-arrival bovine respiratory disease vaccination on ultrasound-confirmed pneumonia and production parameters in male dairy calves: A randomized clinical trial

The high degree of commingling and accumulation of stressors during and after transport makes prevention of bovine respiratory disease (BRD) extremely challenging in the veal and dairy beef industry. Upon arrival, vaccination for agents involved in BRD is practically most achievable, but its efficacy under such conditions in dairy veal calves is unknown. Given the high prevalence of subclinical pneumonia in these settings, the primary objective of the present study was to determine the effect of 2 vaccination protocols administered upon arrival against bovine respiratory syncytial virus (BRSV), bovine parainfluenza type 3 virus (BPI-3), and Mannheimia haemolytica on clinical BRD and lung ultrasonographic findings in dairy veal calves. In addition, the effects of vaccination on average daily live weight gain and cold carcass weight were determined. In this randomized clinical trial, 443 male dairy calves were assigned to one of 3 groups: a negative, placebo-controlled group (n = 151), a vaccination group with 2 subcutaneous injections 4 wk apart with an inactivated vaccine containing BRSV, BPI-3, and M. haemolytica (parenteral [PE] group; n = 149) and a second vaccination group receiving an intranasal live-attenuated vaccine containing BRSV and BPI-3 and 2 subcutaneous vaccinations with the same inactivated vaccine as the PE vaccination group (intranasal-parenteral [IN-PE] group; n = 143). Clinical scoring and quick thoracic ultrasonography (qTUS) were performed on all calves on arrival (wk 0), at the peak of respiratory disease (outbreak; wk 1), at the end of the first antimicrobial group treatment (wk 3), and at a long-term evaluation point (wk 10). Culture and nanopore sequencing on nonendoscopic bronchoalveolar lavage (nBAL) samples were used to identify pathogens involved in the outbreak. Upon arrival, 15.1% of the calves had lung consolidation ≥1cm and incidence quickly rose to 42.8% during the outbreak. In both the PE and IN-PE group, the odds of pneumonia in wk 10 were reduced by 62% (odds ratio [OR] = 0.38; 95% confidence interval [CI] = 0.23-0.64) and 41% (OR = 0.59; 95% CI = 0.37-0.96), respectively. Short-term cure rate (50.3%), as determined immediately after the first group antimicrobial treatment, was not influenced by vaccination. In contrast, long-term cure rate, determined at wk 10, was affected by vaccination with higher cure in the PE group compared with the control group (69.4% vs. 51.2%; OR = 2.2; 95% CI = 1.1-5.0). Average daily gain in the first 10 wk of production was not affected by vaccination. Vaccination resulted in an increase in cold carcass weight of 3.5 and 4.3 kg in the PE (95% CI = -0.9-7.9) and IN-PE group (95% CI = -0.17-8.7), respectively. In conclusion, under the conditions of the present study, vaccination upon arrival resulted in a reduced prevalence of pneumonia at wk 10 of production, likely caused both by an improved cure rate of secondary infections and a reduced incidence of new cases between outbreak and long-term evaluation. The present protocol, using qTUS for pneumonia detection and nBAL diagnostics for pathogen identification adds a new dimension to randomized clinical trials on respiratory disease in calves.

Immune phenotype is differentially affected by changing the type of bovine respiratory disease vaccine administered at revaccination in beef heifers.

During preconditioning, modified-live vaccines are frequently administered to beef calves before weaning. In this study, we began to characterize the immune phenotype of calves that received a modified-live vaccination at 3-4 months of age and then either received the same modified-live or an inactivated vaccine upon arrival at the feedlot (weaning) and 28 days post-arrival (booster). Innate and adaptive immune measures were assessed before revaccination and 14 and 28 days post. Heifers that received three doses of the modified-live vaccine exhibited a relatively balanced immune response based on increases in mean cytokine concentrations (IL-17, IL-21) and total immunoglobulin-G (IgG) and subsets IgG1 and IgG2, which are related to both arms of the adaptive immune system. Conversely, heifers that received one dose of modified live and two doses of the inactivated vaccine had a more robust neutrophil chemotactic response and greater serum-neutralizing antibody titers, resulting in an enhanced innate immune and a skewed proinflammatory response. These results indicate that the revaccination protocol used after initial vaccination with a modified-live vaccine differentially influences the immune phenotype of beef calves, with three doses of modified live inducing potentially immune homeostasis and a combination of modified live and inactivated vaccines inducing a skewed immune phenotype. However, more research is needed to determine the protective efficacy of these vaccination protocols against disease.

Assessment of Rapid MinION Nanopore DNA Virus Meta-Genomics Using Calves Experimentally Infected with Bovine Herpes Virus-1.

Bovine respiratory disease (BRD), which is the leading cause of morbidity and mortality in cattle, is caused by numerous known and unknown viruses and is responsible for the widespread use of broad-spectrum antibiotics despite the use of polymicrobial BRD vaccines. Viral metagenomics sequencing on the portable, inexpensive Oxford Nanopore Technologies MinION sequencer and sequence analysis with its associated user-friendly point-and-click Epi2ME cloud-based pathogen identification software has the potential for point-of-care/same-day/sample-to-result metagenomic sequence diagnostics of known and unknown BRD pathogens to inform a rapid response and vaccine design. We assessed this potential using in vitro viral cell cultures and nasal swabs taken from calves that were experimentally challenged with a single known BRD-associated DNA virus, namely, bovine herpes virus 1. Extensive optimisation of the standard Oxford Nanopore library preparation protocols, particularly a reduction in the PCR bias of library amplification, was required before BoHV-1 could be identified as the main virus in the in vitro cell cultures and nasal swab samples within approximately 7 h from sample to result. In addition, we observed incorrect assignment of the bovine sequence to bacterial and viral taxa due to the presence of poor-quality bacterial and viral genome assemblies in the RefSeq database used by the EpiME Fastq WIMP pathogen identification software.

Variations in antibody repertoires correlate with vaccine responses.

An important challenge in vaccine development is to figure out why a vaccine succeeds in some individuals and fails in others. Although antibody repertoires hold the key to answering this question, there have been very few personalized immunogenomics studies so far aimed at revealing how variations in immunoglobulin genes affect a vaccine response. We conducted an immunosequencing study of 204 calves vaccinated against bovine respiratory disease (BRD) with the goal to reveal variations in immunoglobulin genes and somatic hypermutations that impact the efficacy of vaccine response. Our study represents the largest longitudinal personalized immunogenomics study reported to date across all species, including humans. To analyze the generated data set, we developed an algorithm for identifying variations of the immunoglobulin genes (as well as frequent somatic hypermutations) that affect various features of the antibody repertoire and titers of neutralizing antibodies. In contrast to relatively short human antibodies, cattle have a large fraction of ultralong antibodies that have opened new therapeutic opportunities. Our study reveals that ultralong antibodies are a key component of the immune response against the costliest disease of beef cattle in North America. The detected variants of the cattle immunoglobulin genes, which are implicated in the success/failure of the BRD vaccine, have the potential to direct the selection of individual cattle for ongoing breeding programs.

CattleReview

Introduction: In this Cattle Review we consider three recent papers looking at postpartum uterine disease, Mycoplasma bovis and bovine respiratory disease vaccination.

The Effect of Co-Administration of Inactivated Vaccines Against Bovine Respiratory Disease and Neonatal Calf Diarrhoea

Abstract A pilot study was performed to evaluate the safety and serological responses after co-administration of two multivalent inactivated vaccines to pregnant cattle. One vaccine was directed against bovine respiratory disease (BRD) and contained antigens of bovine respiratory syncytial virus (BRSV), parainfluenza 3 virus (PI3) and Mannheimia haemolytica (Mh). The second vaccine targeted neonatal calf diarrhoea (NCD) and was composed of inactivated antigens of bovine rotavirus (BRV), bovine coronavirus (BCV) and E. coli. The use of these combinations have been used more and more by veterinary practitioners as there exist some clear evidence that both vaccines improves the passive protection via the colostrum for the relevant pathogens. However, up until now, no safety or efficacy data has been available concerning such co-administrations. The safety of both vaccines and the serological responses to the BRD vaccine has been evaluated when used at the same time, but without mixing and compared to the responses to the administration of each vaccine independently. There was no evidence of any negative effect on calving or calf health in any of the vaccinated animals. The antibody levels against BRSV and Mh in the sera of the calves from cows vaccinated with both vaccines were not significantly different from the levels in the sera of calves vaccinated with the BRD vaccine alone. The results from this pilot study demonstrated that the co-administration of the two multivalent inactivated vaccines had no detrimental effect on the safety or serological responses to the BRD vaccine compared to the independent use of the vaccines.

320 Carcass characteristics of Bos indicus-Bos taurus steers following BVDV type 1b challenge

Abstract Bovine Viral Diarrhea virus (BVDV), is a component of bovine respiratory disease (BRD) worldwide. Documentation of animal genetic influences and performance variability specific to BVDV challenge is limited. This study evaluated individual animal effects in the 14 d following BVDV Type 1b intranasal challenge in yearling, Nellore-Angus (Bos indicus-Bos taurus) F2 and F3 crossbred steers (n = 363) on carcass traits 180 d post-challenge. Prior to challenge steers were confirmed to be free of BVDV infection with families balanced across non-vaccinated control, killed (KV), or modified-live (MLV) commercial BRD vaccines. Hot carcass weight (HCW), adjusted fat thickness (AFT), longissimus muscle area (REA) and marbling score (MARB) were analyzed through mixed models with sire and pen(year) as random effects; potential fixed effects of vaccine, type of cross, pyrexia status, clinical sign presentation, and levels of feed intake and ADG 14 d post-challenge were investigated. Vaccine influenced AFT (P = 0.016); MLV steers had 0.26 cm less AFT than KV steers. Marbling was affected by type of cross (P = 0.023) with up to 0.60 marbling scores higher (P < 0.05) in some parental combinations; an interaction between type of cross and pyrexia status also affected MARB (P = 0.017) with one parental combination having higher MARB associated with pyrexia. Hot carcass weight was not affected by pyrexia, but was affected by feed intake (P = 0.019), with steers in the highest vs. lowest category averaging 24.0 kg heavier. No animals presented morbidity signs severe enough for therapeutic treatment, yet presence of mild clinical symptoms affected REA (P = 0.012), resulting in 3.4 cm2 lower REA, however, this pattern was inconsistent among feed intake levels. This study affirms the complexity of health impacts on beef carcass traits and the need for improved study of subclinical illness in beef production systems.

Preweaning cost of bovine respiratory disease (BRD) and cost-benefit of implementation of preventative measures in calves on California dairies: The BRD 10K study

Bovine respiratory disease (BRD) is a multifactorial disease that is estimated to affect 22% of preweaned dairy calves in the United States and is a leading cause of preweaning mortality in dairy calves. Overall cost of calfhood BRD is reflected in both the immediate cost of treating the disease as well as lifetime decrease in production and increased likelihood of affected cattle leaving the herd before their second calving. The goal of this paper was to develop an estimate of the cost of BRD based on longitudinal treatment data from a study of BRD with a cohort of 11,470 preweaned dairy calves in California. Additionally, a cost-benefit analysis was performed for 2 different preventative measures for BRD, an increase of 0.47 L of milk per day for all calves or vaccination of all dams with a modified live BRD vaccine, using differing assumptions about birth rate and number of calves raised per year. Average short-term cost of BRD per affected calf was $42.15, including the use of anti-inflammatory medications in the treatment protocols across all management conditions. The cost of treating BRD in calves appears to have increased in recent years and is greater than costs presented in previous studies. A cost-benefit analysis examined different herd scenarios for a range of cumulative incidences of BRD from 3 to 25%. Increasing milk fed was financially beneficial in all scenarios above a 3% cumulative incidence of BRD. Use of a modified live vaccine in dams during pregnancy, examining only its value as a form of BRD prevention in the calves raised on the farm, was financially beneficial only if the cumulative incidence of BRD exceeded 10 to 15% depending on the herd size and whether the dairy farm was raising any bull calves. The cost-benefit analysis, under the conditions studied, suggests that producers with high rates of BRD may benefit financially from implementing preventative measures, whereas these preventative measures may not be cost effective to implement on dairy farms with very low cumulative incidences of BRD. The long-term costs of calfhood BRD on lifetime productivity were not factored into these calculations, and the reduction in disease may be associated with additional cost savings and an improvement in calf welfare and herd life.

An immunomodulatory feed additive enhances in vitro viral vaccine recall antigen responses in dairy heifers

Enhancing immunological responses to vaccination is an important goal in many herd health management systems. OmniGen-AF®(OG) is an immunomodulatory feed additive that has been shown to enhance innate immune function in ruminants and its effects on adaptive immunity require additional study. The objective of this study was to evaluate post-vaccine antibody titers and circulating cellular memory development in heifers fed OG and administered a commercially available modified-live bovine respiratory disease (BRD) vaccine. Twenty-four Holstein heifers were assigned to one of two diets for 170 days: Control TMR (CON; n = 11), or TMR plus OG (TRT; 9 g/100 kg BW/day; n = 13). Samples for hematology, serology, and cellular assays were collected on D-110, 0, 21, 42, and 60 of the trial. Heifers were administered two priming doses of a modified-live BRD vaccine, with a third dose given on D0. There were no significant differences in total WBC and absolute number or the percentage of circulating lymphocytes, monocytes, neutrophils, RBC, or platelets on D-110 through D21. On D42 and D60, CON had significantly higher numbers of lymphocytes. On D0, mean serum neutralizing (SN) titer to BHV-1 was significantly higher for CON compared to TRT. SN titers were not significantly different between CON and TRT at any other time point for BHV-1, BVDV type 1, or BVDV type 2. TRT mounted a significantly stronger recall proliferative response to 0.5 multiplicity of infection (MOI) of BHV-1, BVDV type 1 and BVDV type 2 on D42 and D60; 0.25 MOI of BVDV type 1 on D21 and D42; and 0.25 MOI BVDV type 2 on D42 compared to CON. IL-4 production induced by 0.5 and 1.0 MOI BHV-1 (D42 and D60); 0.25 MOI of BVDV type 1 (D21); and 0.25 and 0.5 MOI of BVDV type 2 (D60) were significantly higher for TRT than CON. IL-17 production induced by 0.25 MOI of BVDV type 1 was significantly higher on D60 for TRT compared to CON. IFN-gamma and IL-10 were not significantly different between treatments. These data indicate feeding OG has a beneficial effect on responses to vaccine antigens in Holstein dairy heifers.

Epidemiology of bovine respiratory disease (BRD) in preweaned calves on California dairies: The BRD 10K study

Bovine respiratory disease (BRD) is one of the leading causes of death in dairy heifers. The objective of this prospective cohort study was to characterize the epidemiology of BRD in preweaned dairy calves and to identify management practices associated with decreased risk of BRD. Dairies were chosen for the study based on management practices, location, size, and willingness to participate. A total of 6 dairies, ranging in size from 700 to 3,200 milking cows, in 6 counties across California's Central Valley, were enrolled in the study for at least 1 year. A total of 11,945 calves were born on the study dairies and followed until weaning. Incidence of BRD was estimated using treatment records. Trained study personnel performed comprehensive calf management surveys and estimated BRD prevalence on every dairy at least once every season. A shared frailty model was used to model the associations between management practices and BRD hazard. The final models included data from complete records of 11,470 calves. The overall BRD study period prevalence across the study herds was 22.8%. The mean BRD incidence density rate on all the study dairies was 0.17 BRD cases [95% confidence interval (CI) = 0.16-1.74] per calf-month at risk. The shared frailty model identified that feeding only waste or saleable milk (compared with use of milk replacer), feeding over 3.8 L of milk per day to calves under 21 d of age, frequent changing of maternity pen bedding, and administration of modified live or killed BRD vaccines to dams before calving significantly reduced the risk of BRD. Risk factors for BRD included housing calves in wooden hutches with metal roofs, compared with all-wood hutches, twin births, and perception of dust occurring "regularly," as reported by calf managers, compared with a perception of "no dust" in the calf-raising area. All 4 seasons were analyzed, and both summer (hazard ratio = 1.15; 95% CI = 1.01 to 1.32) and spring (hazard ratio = 1.26; 95% CI = 1.11 to 1.44) were associated with a higher risk of BRD compared with winter. The current longitudinal study identified specific housing and feeding practices that could be modified to decrease risk of BRD. In addition, season was observed to have a strong effect on calves' risk of developing BRD on California dairies.

Beef producer survey of the cost to prevent and treat bovine respiratory disease in preweaned calves.

OBJECTIVE To estimate costs associated with prevention and treatment of bovine respiratory disease (BRD) in preweaned calves on US beef cow-calf operations. DESIGN Cross-sectional survey. SAMPLE 43 beef cow-calf producers whose operations had a history of BRD in preweaned calves. PROCEDURES Mail and electronic surveys were developed and administered to producers in Nebraska, North Dakota, and South Dakota to obtain information regarding costs of BRD prevention and treatment. Descriptive statistics were generated. Mixed linear regression models were used to assess factors associated with the costs of vaccines, medicine, and labor and percentage time spent on prevention and treatment of BRD in cows, replacement heifers, and preweaned calves. RESULTS 7 mail and 36 electronic surveys were completed. Median annual costs for BRD vaccines were $2.25, $4.00, and $6.25/animal, and median annual labor costs for vaccination were $4.58, $3.00, and $5.00/animal for cows, heifers, and preweaned calves, respectively. Median annual costs for medicine and labor to treat preweaned calves for BRD were $11.00 and $15.00/ affected calf, respectively. Adjusted mean annual BRD vaccine cost for preweaned calves ($7.67/animal) was significantly greater than that for cows ($3.18/animal) and heifers ($4.48/animal). CONCLUSIONS AND CLINICAL RELEVANCE Results indicated that labor costs associated with BRD vaccination and treatment were similar to or exceeded the cost of vaccines and medicine, and most of those labor costs were associated with gathering and sorting cattle. Therefore, costs associated with labor as well as medicine and vaccines should be considered during the development of BRD prevention and treatment plans.

Potentiation of the humoral immune response elicited by a commercial vaccine against bovine respiratory disease by Enterococcus faecalis CECT7121.

Vaccination against pathogens involved in bovine respiratory disease (BRD) is a useful tool to reduce the risk of this disease however, it has been observed that the commercially available vaccines only partially prevent the infections caused by Pasteurella multocida and Mannheimia haemolytica. Therefore, it is recommended to search for new adjuvant strategies to minimise the economic impact of this respiratory syndrome. A possibility to improve the conventional vaccine response is to modulate the immune system with probiotics, since there is accumulating evidence that certain immunomodulatory strains administered around the time of vaccination can potentiate the immune response. Considering veterinary vaccines are frequently tested in murine models, we have developed an immunisation schedule in BALB/c mice that allows us to study the immune response elicited by BRD vaccine. In order to evaluate a potential strategy to enhance vaccine efficacy, the adjuvant effect of Enterococcus faecalis CECT7121 on the murine specific humoral immune response elicited by a commercial vaccine against BRD was studied. Results indicate that the intragastric administration of E. faecalis CECT7121 was able to induce an increase in the specific antibody titres against the bacterial components of the BRD vaccines (P. multocida and M. haemolytica). The quality of the humoral immune response, in terms of antibody avidity, was also improved. Regarding the cellular immune response, although the BRD vaccination induced a low specific secretion of cytokines in the spleen cell culture supernatants, E. faecalis CECT7121-treated mice showed higher interferon-γ production than immunised control mice. Our results allowed us to conclude that the administration of E. faecalis CECT7121 could be employed as an adjuvant strategy to potentiate humoral immune responses.

Effects of injectable trace minerals on the immune response to Mannheimia haemolytica and Pasteurella multocida following vaccination of dairy calves with a commercial attenuated-live bacterin vaccine

ABSTRACT The objective was to evaluate the effects of an injectable trace mineral (ITM) supplement containing Zn, Mn, Se, and Cu on the humoral and cell mediated immune responses to vaccine antigens in dairy calves receiving an attenuated-live bacterin vaccine containing Mannheimia haemolytica and Pasteurella multocida. Thirty 3-mo-old dairy calves received 2 doses (21 d apart) of an attenuated-live M. haemolytica and P. multocida bacterin vaccine (Once PMH, Merck Animal Health, Summit, NJ), and a 5-way modified-live-virus vaccine (Express 5, Boehringer Ingelheim, Vetmedica, St. Joseph, MO). On the day of primary vaccination, animals were randomly assigned to 1 of the 2 treatment groups (n = 15 per group): ITM (ITM administration) or control (sterile saline injection). Treatments were administered concurrently with vaccinations. Blood samples were collected for determination of antibody titers against M. haemolytica and P. multocida and of antigen-induced proliferation and interferon-γ secretion by peripheral blood mononuclear cells. Serum Se and Mn concentrations were greater (P 0.05) between groups. The use of ITM with bovine respiratory disease vaccines enhanced (P

Effect of suckler cow vaccination against glycoprotein E (gE)-negative bovine herpesvirus type 1 (BoHV-1) on passive immunity and physiological response to subsequent bovine respiratory disease vaccination of their progeny

The study objectives were: 1) to characterise the development of immunocompetence in beef suckler calves from birth to three months of age, and 2) to trace glycoprotein E (gE)-negative bovine herpesvirus type 1 (BoHV-1) antibodies from dam to calf and subsequent vaccination against pneumonia. Thirty multiparous beef suckler, spring-calving cows, consisting of two genotypes were involved; Limousin×Friesian (LF) and Charolais×Limousin (CL). Cows were immunised against the inactivated antigen strain of BoHV-1 (gE- (IBR marker vaccine) at day −84 and received a booster at day −56 relative to the expected calving date (d 0). Calves were immunised at 14 and 42days of age against PI-3 virus, BRSV and Mannheimia (Pasteurella) haemolytica serotype A1 using a commercial vaccine administered subcutaneously. Additionally, calves were immunised against BoHV-1 at 42days of age, using 1 dose of a live commercial vaccine administered intranasally. Blood samples were collected from all calves (n=30) via jugular venipuncture at birth, prior to colostrum feeding (0h), at 12h (h), 24h, 72h and 168h after the initial feeding of colostrum, and at d 7, 14, 28, 42, 56 and 84 post birth. The mean ratio of gE negative antibodies circulating in the blood of LF and CL dams pre-partum scored negative to gE ab (S/N≥0.70). Antibody levels of BoHV-1 (wild type (wt)) peaked at 12h post-birth in calves and declined thereafter, as the maternal antibodies decayed. There was no difference in BoHV-1 and BRSV antibody levels in calves post vaccination.

Associations between exposure to viruses and bovine respiratory disease in Australian feedlot cattle

Bovine respiratory disease (BRD) is the most important cause of clinical disease and death in feedlot cattle. Respiratory viral infections are key components in predisposing cattle to the development of this disease. To quantify the contribution of four viruses commonly associated with BRD, a case-control study was conducted nested within the National Bovine Respiratory Disease Initiative project population in Australian feedlot cattle. Effects of exposure to Bovine viral diarrhoea virus 1 (BVDV-1), Bovine herpesvirus 1 (BoHV-1), Bovine respiratory syncytial virus (BRSV) and Bovine parainfluenza virus 3 (BPIV-3), and to combinations of these viruses, were investigated.Based on weighted seroprevalences at induction (when animals were enrolled and initial samples collected), the percentages of the project population estimated to be seropositive were 24% for BoHV-1, 69% for BVDV-1, 89% for BRSV and 91% for BPIV-3.For each of the four viruses, seropositivity at induction was associated with reduced risk of BRD (OR: 0.6–0.9), and seroincrease from induction to second blood sampling (35–60 days after induction) was associated with increased risk of BRD (OR: 1.3–1.5). Compared to animals that were seropositive for all four viruses at induction, animals were at progressively increased risk with increasing number of viruses for which they were seronegative; those seronegative for all four viruses were at greatest risk (OR: 2.4). Animals that seroincreased for one or more viruses from induction to second blood sampling were at increased risk (OR: 1.4–2.1) of BRD compared to animals that did not seroincrease for any viruses. Collectively these results confirm that prior exposure to these viruses is protective while exposure at or after feedlot entry increases the risk of development of BRD in feedlots. However, the modest increases in risk associated with seroincrease for each virus separately, and the progressive increases in risk with multiple viral exposures highlights the importance of concurrent infections in the aetiology of the BRD complex. These findings indicate that, while efficacious vaccines could aid in the control of BRD, vaccination against one of these viruses would not have large effects on population BRD incidence but vaccination against multiple viruses would be expected to result in greater reductions in incidence. The findings also confirm the multifactorial nature of BRD development, and indicate that multifaceted approaches in addition to efficacious vaccines against viruses will be required for substantial reductions in BRD incidence.

Serological effect of two concurrent IBRV, BVDV, BRSV, PI3V, and Mannheimia haemolytica vaccination protocols and time interval between the first and second dose on the subsequent serological response to the BRSV and M. haemolytica fractions in suckling beef calves

This study was conducted to compare the serologic response of suckling beef calves to the bovine respiratory syncytial virus (BRSV) and Mannheimia haemolytica fractions of 2 bovine respiratory disease (BRD) vaccination protocols when the second dose was given 153 days after the first dose. Calves in 1 group were vaccinated with intranasal (IN) modified-live virus (MLV) 3-way BRD vaccine plus separate subcutaneous (SC) injections of MLV bovine viral diarrhea virus (BVDV) type 1 and 2 vaccine and M. haemolytica bacterin-leukotoxoid. Calves in the other group were vaccinated with SC MLV 5-way BRD vaccine combined with M. haemolytica leukotoxoid. On day 153, all calves were revaccinated with SC MLV 5-way vaccine combined with M. haemolytica leukotoxoid. Both calf vaccination protocols stimulated a humoral immune response to the BRSV and M. haemolytica vaccine fractions. Vaccination with IN MLV 3-way BRD vaccine resulted in a significantly (P=0.003) higher initial antibody response to BRSV and a significantly (P=0.006) higher anamnestic response. No differences were seen between groups in initial M. haemolytica leukotoxoid antibody levels. Vaccination with SC MLV 5-way BRD vaccine combined with M. haemolytica leukotoxoid resulted in a significantly (P=0.02) higher anamnestic response to M. haemolytica leukotoxoid.